Right and left ventricular response to subcutaneous terbutaline in patients with chronic obstructive pulmonary disease: radionuclide angiographic assessment of cardiac size and function.
To assess the response of the right and left ventricles to the subcutaneous administration of terbutaline sulfate, a beta-2 selective agonist, we evaluated 14 patients with chronic obstructive pulmonary disease (COPD) with equilibrium radionuclide angiography (RNA). Prior to injection, eight patients (57%) had an abnormal right ventricular ejection fraction (RVEF), four (29%) had a low left ventricular ejection fraction (LVEF), and three (21%) had low ejection fractions of both ventricles. After terbutaline injection, RVEF increased in 13 of 14 patients (93%) by 17 +/- 8% (p less than 0.001) while LVEF increased in all patients by 15 +/- 7% (p less than 0.001). Both left and right ventricular end-diastolic volumes decreased (p less than 0.01), while stroke volume was unchanged. Cardiac output rose by 0.8 +/- 1.3 L/min (p less than 0.05), primarily due to the increase in heart rate (10 bpm, p less than 0.001), since stroke volume did not significantly change. We conclude that in patients with COPD subcutaneous terbutaline has significant beta-1 cardiac effects; it increases the heart rate and decreases cardiac size.
D000368:Aged; D001794:Blood Pressure; D002302:Cardiac Output; D006321:Heart / Q000000981:diagnostic imaging*; D006339:Heart Rate; D006439:Hemodynamics; D006801:Humans; D007279:Injections, Subcutaneous; D008173:Lung Diseases, Obstructive / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D013318:Stroke Volume; D013726:Terbutaline / Q000008:administration & dosage*
D013726:Terbutaline